| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Pyxis Oncology, Inc. | Director | Stock Option (Right to Buy) | 36,979 | $36,239 | $0.9800 | 31 Mar 2025 | Direct |
| Pyxis Oncology, Inc. | Director | Common Stock | 6,000 | $11,760 | $1.96 | 07 Jun 2024 | Direct |
| Acrivon Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 20,275 | 13 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | 13 Jun 2025 | 1 | $0 | 4 | Director | 17 Jun 2025, 17:49 |
| PYXS | Pyxis Oncology, Inc. | 31 Mar 2025 | 1 | +$36,239 | 4 | Director | 02 Apr 2025, 08:58 |
| PYXS | Pyxis Oncology, Inc. | 07 Jun 2024 | 1 | $0 | 4 | Director | 07 Jun 2024, 17:00 |
| PYXS | Pyxis Oncology, Inc. | 12 Mar 2024 | 1 | $0 | 4 | Director | 13 Mar 2024, 16:54 |
| PYXS | Pyxis Oncology, Inc. | 12 Mar 2024 | 0 | $0 | 3 | Director | 13 Mar 2024, 16:45 |
| ACRV | Acrivon Therapeutics, Inc. | 04 Mar 2024 | 1 | $0 | 4 | Director | 06 Mar 2024, 16:32 |
| ACRV | Acrivon Therapeutics, Inc. | 04 Mar 2024 | 0 | $0 | 3 | Director | 06 Mar 2024, 16:29 |